Chromadex Corp Stock Price, News & Analysis

ChromaDex Corp. (CDXC) reported record revenue of $21.0 million for Q4 2022, an 18% increase year-over-year. Tru Niagen® sales rose by 14% to $16.1 million. Despite a net loss of $1.4 million, adjusted EBITDA improved to a profit of $0.4 million, reflecting operational efficiency. Full year sales totaled $72.0 million, up 7%, driven by e-commerce growth. The company signed a long-term agreement with Nestlé Health Science and received two new U.S. patents. Looking ahead, ChromaDex expects at least 10% revenue growth in 2023 amidst economic uncertainty, while projecting stable gross margins and reduced administrative expenses.

ChromaDex Corp. (NASDAQ:CDXC) announced its participation at the 35th Annual ROTH Capital Partners Conference in Dana Point, CA. CEO Rob Fried will present in a fireside chat on March 13th at 11:00 a.m. PT, highlighting ChromaDex's dedication to healthy aging and its pioneering research on NAD+.

The event, one of the largest for small-cap companies, includes presentations, Q&A sessions, and one-on-one meetings with investors. ChromaDex has been recognized as a distinguished healthcare sector presenter.

For more details, visit www.chromadex.com.

ChromaDex Corp. (NASDAQ:CDXC) will hold a conference call on March 8, 2023, at 4:30 p.m. ET to discuss its fourth quarter and fiscal year 2022 financial results, with results released post-market. Participants are encouraged to dial in 10 minutes prior. The call will be available for replay from 7:30 p.m. ET on March 8 to 11:59 p.m. ET on March 14. ChromaDex specializes in bioscience focused on healthy aging and is known for its innovative NAD+ precursor, Niagen®. The company emphasizes research on nicotinamide adenine dinucleotide (NAD+) and its effects on aging.

ChromaDex Corp. (NASDAQ: CDXC) has expanded its patent portfolio for dihydronicotinamide riboside (NRH) with U.S. Patent 11,584,770, securing composition claims for purities over 90% chemical and 98% beta. This patent bolsters ChromaDex's leadership in the NAD+ precursor sector, allowing for future innovations in health supplements and pharmaceuticals. Preclinical studies suggest NRH is a potent NAD+ precursor, potentially outperforming existing options. The patent offers protection until 2034, enhancing the commercial viability of NRH and related products.

ChromaDex (NASDAQ: CDXC) provided an update on its intellectual property following a U.S. Court of Appeals decision affirming the invalidity of the 807 Dartmouth patent. The company asserts this judgment will not materially impact its nicotinamide riboside (NR) business, as it holds new patents obtained last year, ensuring protection for NR for at least the next 10 years. The patents cover methods of making NR and its various salt forms. ChromaDex emphasizes the strength of its brand, Tru Niagen®, backed by rigorous scientific studies. Looking ahead, the company plans to announce innovations in the coming months.

ChromaDex Corp. (NASDAQ:CDXC) announced positive results from its first-ever human clinical trial on combined metabolic activator (CMA) supplementation for Alzheimer's disease (AD) patients. The study, detailed in the peer-reviewed journal Translational Neurodegeneration, involved 60 patients and showed a 29% improvement in cognitive function compared to only 14% in the placebo group after 84 days. CMA, which includes the proprietary niagen® ingredient alongside L-carnitine and others, also enhanced liver and kidney health markers. ChromaDex plans to initiate a Phase 3 study for further research into CMA as a therapeutic option for AD.

ChromaDex Corp. (NASDAQ:CDXC) announced results from a pioneering five-month clinical study on its proprietary ingredient, Niagen® (nicotinamide riboside or NR). The study, involving 20 identical twin pairs, demonstrated that NR supplementation significantly improved muscle mitochondrial biogenesis, satellite cell differentiation, and gut microbiota composition. Results were published in Science Advances, marking a milestone as the longest NR supplementation study to date. NR increased mitochondrial DNA by ~30% and showed well-tolerance. However, the study had limitations, including a lack of parallel placebo arm for BMI-discordant twins, prompting further investigations.